An evaluation of a low‐cost platelet‐rich plasma for osteoarthritis of the knee: A pilot study

Le résumé fourni par la source

Abstract Purpose To assess the characteristics and effectiveness of low‐cost platelet‐rich plasma (LC‐PRP) for knee osteoarthritis (OA) by evaluating its composition and effect on pain, function, satisfaction, safety and cost‐effectiveness. Methods Level IV evidence single‐arm prospective cohort pilot study of 20 subjects (30 knees total) with mild‐to‐moderate knee OA. Two LC‐PRP injections were performed, 3 weeks apart. Platelet extraction/yield, patient‐reported outcomes and incidence of adverse events were assessed with a primary endpoint of 6 months. A cost‐effectiveness analysis of LC‐PRP compared to corticosteroid injection was conducted. Results On average, this LC‐PRP preparation method allowed for recovery of 85% of platelets. Significant mean differences in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores (total, pain and function) and global assessment score were observed at all follow‐up points compared to baseline ( p < 0.05 for 1, 3, 6 and 12 months). Satisfaction was noted in 90% of patients at 6 months and 75% of patients at 12 months. No significant adverse events were reported. LC‐PRP was less costly ($654 vs. $1308) and yielded more QALYs (0.846 vs. 0.708) than corticosteroid injections. Per injection costs were estimated to be $10 for corticosteroid and $11 for LC‐PRP. Conclusions This pilot study demonstrates that LC‐PRP ($11) may significantly benefit patients with knee OA. LC‐PRP appears to be a safe, cost‐effective means for improving pain and function in knee OA. Level of Evidence Level IV.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.